SOPHiA GENETICS Enhances Collaboration with AstraZeneca
SOPHiA GENETICS (Nasdaq: SOPH), a leading healthcare technology company, is excited to announce an expanded partnership with AstraZeneca focused on boosting the global implementation of innovative liquid biopsy testing methods. This collaboration builds upon their previous working relationship, furthering aims to transform cancer diagnostics through advanced data-driven solutions.
Innovative Liquid Biopsy Testing Development
The collaboration revolves around the MSK-ACCESS® application, powered by SOPHiA DDM™, which has been developed in conjunction with the renowned Memorial Sloan Kettering Cancer Center. This state-of-the-art platform empowers healthcare providers to conduct effective liquid biopsy testing, allowing clinicians to isolate actionable genomic changes from a singular blood sample. This method significantly enhances patient care, especially in scenarios where traditional tissue biopsies may be impractical due to high costs or logistical challenges.
Expanding the Reach of Liquid Biopsy Testing
The upcoming rollout aims to extend testing to 30 clinical institutions globally within the year. This expansion is expected to play a pivotal role in further establishing AstraZeneca’s initiatives in real-world evidence gathering. By validating the efficacy of decentralized liquid biopsy testing, the collaboration hopes to enhance the integration of these advanced testing methods within various healthcare systems, potentially leading to improved patient outcomes and laboratory efficiencies.
Presenting Groundbreaking Data at a Major Conference
The announcement aligns with SOPHiA GENETICS’s recent presentation at a prominent annual meeting, where they showcased significant findings related to the transferability and accuracy of the MSK-ACCESS® powered with SOPHiA DDM™ solution. Through extensive real-world data analyses, the company provided compelling evidence supporting the reliability and consistency of their liquid biopsy tests across different laboratories, addressing a key barrier to adoption.
Commitment to Next-Generation Oncology Diagnostics
As SOPHiA GENETICS continues to transform cancer diagnostics, Ross Muken, the President of SOPHiA GENETICS, emphasized the importance of this partnership. He stated that this collaboration marks a significant innovation in oncology diagnostics and underlines the collective drive to make advanced liquid biopsy technologies more accessible on a global scale.
More About SOPHiA GENETICS
SOPHiA GENETICS aims to enhance access to data-driven medicine through cutting-edge technologies. Their flagship SOPHiA DDM™ platform delivers invaluable insights by analyzing complex genomic data, fostering advancements in patient care. The company's networks span hospitals, laboratories, and biopharmaceutical institutions, ensuring a broad impact in the fight against cancer and rare diseases.
Frequently Asked Questions
What is liquid biopsy testing?
Liquid biopsy testing is a non-invasive method to analyze circulating tumor DNA from a blood sample, enabling early cancer detection and monitoring.
How does the collaboration between SOPHiA GENETICS and AstraZeneca enhance cancer diagnostics?
This collaboration enhances the analysis of genomic alterations, broadening availability and enabling real-time treatment options for cancer patients.
What are the benefits of using MSK-ACCESS® powered with SOPHiA DDM™?
The platform allows for faster and less invasive testing, aiding in timely clinical decisions without the complications associated with traditional biopsies.
Where can I learn more about SOPHiA GENETICS?
For more information, visit SOPHiAGENETICS.COM or connect with them on LinkedIn for the latest updates.
How does this collaboration impact cancer research?
The partnership aims to gather real-world evidence, improving the understanding of how decentralized testing can be integrated into various healthcare systems.
